Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ayumi Walks Away from JPMA, Plans to Join JGA
August 23, 2023
- Mounjaro Makes Comeback as No 1 in GP Promotion, Tarlige Tops HP List in June: Intage
August 23, 2023
- Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
August 23, 2023
- Iveric Bio’s AMD Drug Accepted for EMA Review: Astellas
August 21, 2023
- Opdivo Yet Again Frontrunner, Keytruda Follows in April-June: IQVIA
August 18, 2023
- Solo Januvia Generic Approval Likely Exploited Patent Loophole, Litigation Possible?
August 18, 2023
- Takeda Files cTTP Therapy ADAMTS-13 in Japan
August 18, 2023
- Ex-Takeda Japan Chief Looks to Tackle Social Security Issues via Biz Lobby
August 17, 2023
- BMS Unit Wins Japan Approval for Sprycel Authorized Generic
August 17, 2023
- Healios Sets Up R&D Subsidiary for eNK Cells
August 16, 2023
- Moderna Japan Chief to Bow Out at Year-End for Personal Reasons
August 14, 2023
- Novo Nordisk Files Once-Weekly Basal Insulin in Japan
August 10, 2023
- Astellas to Open New Life Sciences Facility in Greater Boston Area
August 10, 2023
- Japan Ethical Drug Sales Up 8.8% in June: Crecon
August 10, 2023
- Nippon Shinyaku Gets EU Orphan Tag for Myelofibrosis Med
August 9, 2023
- Otsuka Unit Astex, Merck Expand Drug Discovery Alliance
August 9, 2023
- Astellas Puts Up US$50 Million for CAR-T Player Poseida
August 9, 2023
- Astellas Set to Cut Development Time with Cell Culture Robot, Eyes 4 Billion Yen Profit per Product
August 9, 2023
- Shipment Restrictions Now Hit All Versions of Mounjaro in Japan
August 8, 2023
- Daiichi Sankyo to Shutter R&D Subsidiary in Tokyo in Group Rejig
August 8, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…